Type 2 diabetes mellitus (T2DM) medicines – amended PBS restrictions
Key Points
- On 1 June 2024, PBS restrictions for type 2 diabetes mellitus (T2DM) medicines changed.
- The changes relate to PBS authority level restrictions for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and PBS restrictions for other T2DM medicines.5
- These changes have been made in accordance with PBAC recommendations to:
- simplify and clarify the PBS restrictions
- ensure use of these medicines in line with the PBS restrictions
- align restrictions with current clinical guidelines while considering the cost-effectiveness of comparative treatments.5
- PBS restriction changes to type 2 diabetes mellitus (T2DM) medicines. Canberra: Australian Government Department of Health and Aged Care; 2024 Available from: www.pbs.gov.au/info/reviews/pbs-restriction-changesto-type-2-diabetes-mellitus-t2dm-medicines (accessed 6 June 2024)